The 12 most recent market catalysts affecting $AHCO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bearish
Impact 55
Baird Maintains Outperform on AdaptHealth, Lowers Price Target to $9
Baird's decision to lower AdaptHealth's price target from $10 to $9, while maintaining an 'Outperform' rating, signals a nuanced view. This adjustment suggests that while the analy…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 55
UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10
UBS analyst Kevin Caliendo lowered AdaptHealth's price target from $14 to $10, while still maintaining a 'Buy' rating. This adjustment suggests that while the analyst still sees up…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 65
RBC Capital Maintains Outperform on AdaptHealth, Lowers Price Target to $8
RBC Capital's decision to lower AdaptHealth's price target from $15 to $8, while maintaining an 'Outperform' rating, signals a significant re-evaluation of the company's near-term …
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 55
Truist Securities Maintains Buy on AdaptHealth, Lowers Price Target to $9
Truist Securities analyst David Macdonald maintained a 'Buy' rating on AdaptHealth (AHCO) but lowered the price target from $14 to $9. This action indicates that while the analyst …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Tuesday's Intraday Session
The filing highlights substantial intraday price swings for a dozen healthcare stocks, with several explicitly linking these movements to their Q2 earnings reports. This indicates …
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 95
UPDATE: AdaptHealth Q2 Adj. EPS $0.08 Misses $0.17 Estimate
AdaptHealth (AHCO) announced its Q2 earnings, reporting an adjusted EPS of $0.08, which fell short of the analyst consensus of $0.17 by a substantial 52.94%. This underperformance …
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
AdaptHealth shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a significant corporate catalyst for AdaptHealth (AHCO). The combination of a Q2 earnings miss and a downward revision of long-term sales guidance (FY26) s…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This filing details the pre-market performance of 12 healthcare stocks, with several experiencing significant volatility. The primary catalyst for these movements appears to be the…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
AdaptHealth Lowers FY2026 Sales Guidance from $3.450B-$3.520B to $2.850B-$2.890B vs $3.488B Est
AdaptHealth (AHCO) announced a substantial reduction in its FY2026 sales guidance, lowering the projected range from $3.450B-$3.520B to $2.850B-$2.890B. This represents an approxim…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 95
AdaptHealth Q2 EPS $(0.99) Misses $0.18 Estimate, Sales $740.300M Miss $848.627M Estimate
AdaptHealth (AHCO) announced Q2 earnings per share of $(0.99), missing the analyst consensus of $0.18 by a staggering 650%. This represents a 1090% decrease from the prior year. Ad…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Upgrades AdaptHealth to Buy, Raises Price Target to $13
Jefferies analyst Brian Tanquilut upgraded AdaptHealth (AHCO) from a 'Hold' to a 'Buy' rating and raised the price target from $11 to $13. This action signals increased confidence …
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 95
AdaptHealth Divests Diabetes Health Business To Cardinal Health For $235M In Cash
AdaptHealth (AHCO) announced the divestiture of its Diabetes Health business to Cardinal Health (CAH) for $235 million in cash. This is a significant strategic move for AHCO, allow…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.